

Marc R Kok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8327454/publications.pdf>

Version: 2024-02-01

43
papers

1,435
citations

393982

19
h-index

329751

37
g-index

44
all docs

44
docs citations

44
times ranked

1492
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-Analyses on the Effects of Disease-Modifying Antirheumatic Drugs on the Most Relevant Patient-Reported Outcome Domains in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2023, 75, 1659-1672.	1.5	1
2	The burden of psoriasis in patients with early psoriatic arthritis. <i>Rheumatology</i> , 2022, 61, 1570-1578.	0.9	3
3	Characterizing memory T helper cells in patients with psoriasis, subclinical, or early psoriatic arthritis using a machine learning algorithm. <i>Arthritis Research and Therapy</i> , 2022, 24, 28.	1.6	4
4	Paternal inflammatory arthritis is associated with a higher risk of miscarriage: results of a large multicentre study (iFAME-Fertility). <i>Rheumatology</i> , 2022, 61, 3390-3395.	0.9	4
5	Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals. <i>Rheumatology</i> , 2022, 62, 52-64.	0.9	3
6	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 925-936.	0.5	59
7	Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. <i>Rheumatology</i> , 2022, 62, 330-334.	0.9	4
8	Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. <i>Arthritis Care and Research</i> , 2021, 73, 100-109.	1.5	19
9	Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1545-1552.	0.5	15
10	Single-Cell RNA Sequencing Reveals Heterogeneity and Functional Diversity of Lymphatic Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11976.	1.8	9
11	Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögrens syndrome. <i>European Journal of Immunology</i> , 2020, 50, 119-129.	1.6	39
12	Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. <i>RMD Open</i> , 2020, 6, e001175.	1.8	4
13	Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9544.	1.8	8
14	Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. <i>Lancet Rheumatology</i> , The, 2019, 1, e145-e153.	2.2	19
15	Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2019, 21, 208.	1.6	3
16	Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 25.	1.6	12
17	Comparison of disease activity measures in early psoriatic arthritis in usual care. <i>Rheumatology</i> , 2019, 58, 2251-2259.	0.9	20
18	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. <i>BMC Rheumatology</i> , 2019, 3, 3.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1711-1722.	2.9	13
20	Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 610-616.	0.5	33
21	LB0010â€¦.ULTRA-LOW DOSES OF RITUXIMAB OR RETREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL. , 2019, , .		0
22	SAT0401â€¦.USE OF AND RESPONSE TO METHOTREXATE IN EARLY PSORIATIC ARTHRITIS: RESULTS FROM THE REAL WORLD COHORT, DEPAR STUDY. , 2019, , .		1
23	AB0395â€¦.NO CLINICAL RELEVANT CHANGES IN EFFICACY, QUALITY OF LIFE AND TOLERABILITY FOR RA PATIENTS IN CLINICAL REMISSION 16 WEEKS AFTER SWITCHING TO THE BIOSIMILAR IFX CT-P13 COMPARED TO THE ORIGINATOR; A DESCRIPTIVE REPORT. , 2019, , .		0
24	Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. <i>Rheumatology</i> , 2019, 58, 1344-1352.	0.9	79
25	Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab â€” The GO-EASY Study. <i>Journal of Rheumatology</i> , 2019, 46, 153-159.	1.0	43
26	Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 1764-1770.	1.5	29
27	Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. <i>Clinical Rheumatology</i> , 2018, 37, 909-916.	1.0	12
28	Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 1320-1325.	1.5	49
29	Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1526-1531.	1.0	34
30	Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. <i>Atherosclerosis</i> , 2013, 229, 174-181.	0.4	85
31	Taking advances from bench to bedside during the last decade. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 225-236.	1.4	5
32	Remission of Incapacitating Acute Cutaneous Lupus Erythematosus in a Patient With Systemic Lupus Erythematosus by B Cell-Depletive Therapy. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 345.	0.5	1
33	Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2009, 11, R189.	1.6	26
34	Re-engineering Primary Epithelial Cells from Rhesus Monkey Parotid Glands for Use in Developing an Artificial Salivary Gland. <i>Tissue Engineering</i> , 2006, 12, 2939-2948.	4.9	40
35	Re-engineering Primary Epithelial Cells from Rhesus Monkey Parotid Glands for Use in Developing an Artificial Salivary Gland. <i>Tissue Engineering</i> , 2006, .	4.9	0
36	Immune responses following salivary gland administration of recombinant adeno-associated virus serotype 2 vectors. <i>Journal of Gene Medicine</i> , 2005, 7, 432-441.	1.4	24

#	ARTICLE	IF	CITATIONS
37	Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. <i>Journal of Endocrinology</i> , 2005, 185, 363-372.	1.2	69
38	Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 3053-3058.	3.3	92
39	Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 2240-2245.	6.7	260
40	Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2004, 51, 601-604.	6.7	50
41	Advances in vector-mediated gene transfer. <i>Immunology Letters</i> , 2003, 90, 145-149.	1.1	33
42	Local Adeno-Associated Virus-Mediated Interleukin 10 Gene Transfer Has Disease-Modifying Effects in a Murine Model of Sjögren's Syndrome. <i>Human Gene Therapy</i> , 2003, 14, 1605-1618.	1.4	191
43	The impact of gene therapy on dentistry. <i>Journal of the American Dental Association</i> , 2002, 133, 35-44.	0.7	35